fluorouracil has been researched along with Adenocarcinoma Of Kidney in 212 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 7.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| " Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment." | 3.81 | Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "We found eight patients with renal cell carcinoma who developed carpal tunnel syndrome (CTS) during treatment with IL-2, fluorouracil (5-FU), and alpha-interferon (alpha-IFN)." | 3.69 | Carpal tunnel syndrome associated with interleukin-2 therapy. ( Austin, SG; Forman, AD; Puduvalli, VK; Sella, A, 1996) |
| "Capecitabine has clinical activity in MRCC patients who have non-clear cell histology and a good or intermediate prognosis." | 2.77 | Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. ( Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I, 2012) |
| "We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy." | 2.77 | Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "Capecitabine was administered 2,000 mg/m(2) daily for 14 days followed by 1 week rest." | 2.75 | A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. ( Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL, 2010) |
| "In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents." | 2.75 | Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. ( Aitchison, M; Gore, ME; Griffin, CL; Hancock, B; Hussain, T; James, N; Mardiak, J; Mulders, PF; Oliver, RT; Parmar, MK; Patel, PM; Pyle, L; Royston, P; Sylvester, R, 2010) |
| "The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease." | 2.74 | Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. ( Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG, 2009) |
| "Fifty-five (55) patients with renal cell cancer were randomly divided into a Haishengsu group (n = 27, 2." | 2.74 | Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial. ( Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B; Zhao, XW, 2009) |
| "Metastatic renal carcinoma patients without prior fluoropyrimidine therapy and normal organ function were treated with oral capecitabine 880 mg/m(2) twice daily along with continuous infusion GTI-2040 starting at 148 mg/m(2)/day for 21 days, for each 28-day cycle." | 2.73 | A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. ( Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM, 2008) |
| "Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy." | 2.73 | Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. ( Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A, 2007) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "Sixty-two patients with metastatic renal cell carcinoma participated in a Phase II study." | 2.73 | Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel. ( Best, LA; Gaitini, D; Gez, E; Kuten, A; Mashiach, T; Meretyk, S; Native, O; Rubinov, R; Stein, A, 2007) |
| " The suramin dosing nomogram used in phase I and II portions of the trial yielded the desired plasma level of 10-50 micromol/L from 4." | 2.73 | Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. ( Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008) |
| "The median time to disease progression was 9." | 2.73 | [A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy]. ( Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M, 2008) |
| "This prospective trial aimed to evaluate the therapeutic effects and systemic toxicities of capecitabine monotherapy and capecitabine treatment combined with biological response modifiers in patients with metastatic renal cell carcinoma." | 2.71 | Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. ( Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC, 2003) |
| "5-Fluorouracil was given at 750 mg m(-2) day(-1) on days 1-5 every 4 weeks." | 2.71 | Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. ( Bui, BN; Cany, L; Debled, M; Ferrière, JM; Gaston, R; Mathoulin-Pélissier, S; Palussière, J; Ravaud, A; Trufflandier, N, 2003) |
| "Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)." | 2.71 | A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. ( Rini, BI; Small, EJ; Weinberg, V, 2005) |
| "In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0)." | 2.71 | Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). ( Atzpodien, J; Ecke, M; Fornara, P; Gertenbach, U; Heynemann, H; Jentsch, H; Maskow, A; Reitz, M; Schmitt, E; Wandert, T; Wieland, W; Wöltjen, HH, 2005) |
| "The treatment of metastatic renal cell cancer remains unsatisfactory despite encouraging results with biotherapy." | 2.70 | Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. ( Church, CK; DePriest, CB; Dillman, RO; Schulof, R; Soori, G; Stark, JJ; Tai, F; Wiemann, MC, 2002) |
| "The authors present the results of a six-year clinicoimmunological study of a therapeutic effect of cytkins combined with 5-fluoruracyl in metastatic renal-cell carcinoma." | 2.70 | [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer]. ( Babich, VM; Bazalitskaia, SV; Gruzov, MA; Klimenko, IA; Kushneruk, IuI; Romanenko, AM; Shcherbak, AIu; Vozianov, AF; Zak, KP; Zubko, VI, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| "Chemotherapy resistance of renal cell carcinoma (RCC) has been attributed in large part to multidrug resistance (MDR)." | 2.70 | Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. ( Chang, YH; Chen, KK; Chen, PM; Fan, FS; Liu, JH; Wang, WS; Yang, MH; Yen, CC, 2001) |
| "The median time to disease progression was 6." | 2.70 | A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. ( Ryan, CW; Stadler, WM; Vogelzang, NJ, 2002) |
| " Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks." | 2.70 | Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001) |
| "Twenty-one patients with metastatic renal cell carcinoma (RCC) and a Cancer and Leukemia Group B performance status of 0 to 2 were enrolled." | 2.70 | A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. ( Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ, 2002) |
| "Combination therapy of interferon-alpha plus 5-fluorouracil at the above-described dosage and schedule produced no better responses than interferon monotherapies." | 2.69 | Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer. ( Aiba, K; Igarashi, T; Kawamura, J; Kobayashi, M; Marumo, K; Onishi, T; Ozono, S; Satomi, Y; Terachi, T; Tomita, Y; Tsushima, T, 1999) |
| " During weeks 1 and 4, the dosage for rIL-2 was 10 MIU/m2 twice daily on days 3-5, and the dosage for IFN-alpha2B (Intron; Schering Plough, Kenilworth, NJ) was 6 MIU/m2 on day 1." | 2.69 | Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. ( Atkins, M; Clark, J; Dutcher, JP; Gordon, M; Logan, T; Lotze, M; Margolin, K; Mier, J; Plasse, T; Sosman, J; Weiss, G, 2000) |
| "55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-alpha according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m(-2)day(-1)during weeks 5-9." | 2.69 | Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. ( Ahern, R; Allen, MJ; Bate, S; Eisen, T; Gore, ME; Johnston, S; Moore, J; Savage, P; Vaughan, M; Webb, A, 2000) |
| "In patients with metastatic renal cell carcinoma response rates of 7-26% have been achieved with immunotherapy." | 2.69 | Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. ( De Mulder, PH; Groenewegen, G; Hoekman, K; Jansen, RL; Kruit, WH; Osanto, S; van Herpen, CM, 2000) |
| "Among 16 patients with renal cell carcinoma treated, four had major (clinical partial response) responses, one of which was demonstrated to be a pathologic clinical response after surgical resection of a residual mass." | 2.69 | Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. ( Altobelli, KK; Binder, M; Clark, D; Elias, L; Mangalik, A; Morrison, B; Smith, A, 1999) |
| "Cimetidine is an H2-receptor antagonist used in the management of peptic ulcer disease and other hypersecretory gastrointestinal disorders." | 2.69 | A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. ( Burch, PA; Creagan, ET; Dalton, RJ; Hatfield, AK; Maples, WJ; Pfeifle, DM; Poon, MA; Schaefer, PL; Suman, VJ; Veeder, MH, 1998) |
| "We report the results of the Subcutaneous Administration Propeukin Program (SCAPP) II trial of an outpatient treatment in renal cell carcinoma using interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) administered subcutaneously in combination with fluorouracil (5-FU)." | 2.69 | Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr ( Abourachid, H; Andrieu, JM; Azagury, M; Benhammouda, A; Berdah, JF; Brewer, Y; Chastang, C; Chretien, Y; Di Palma, M; Guillet, P; Hauteville, D; Krakowski, I; Larregain-Fournier, D; Lucas, V; Malaurie, E; Mayeur, D; Mejean, A; Monnier, A; Paule, B; Pavlovitch, JM; Pfister, C; Salze, P; Tadrist, Z; Tourani, JM; Untereiner, M, 1998) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | 2.68 | [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Renal cell carcinoma is a common neoplasm that is often refractory to treatment." | 2.68 | A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. ( Blumenstein, BA; Crawford, ED; Elias, L; Flanigan, RC; Goodwin, JW; Kish, J; Lowe, BA; Wade, JL, 1996) |
| "5-fluorouracil was administered at a dose of 600 mg/m2/day as a continuous infusions on Days 1-5." | 2.68 | Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. ( Amato, RJ; Banks, M; Ellerhorst, JA; Finn, LD; Logothetis, CJ; Millikan, RE; Sella, A; Tu, SM, 1997) |
| "Renal cell carcinoma is relatively resistant to both chemotherapy and immunotherapy." | 2.68 | Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. ( Carpenter, C; Gebrosky, NP; Koukol, S; Lamm, DL; Nseyo, UO, 1997) |
| " None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU." | 2.68 | [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995) |
| "In patients with progressive metastatic renal cell carcinoma, we established a three-drug combination comprising interferon-alpha (IFN-alpha), interleukin-2 (IL-2) and 5-fluorouracil (5-FU), using a regimen which allows outpatient therapy." | 2.67 | Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. ( Atzpodien, J; Deckert, M; Fenner, M; Hänninen, EL; Kirchner, H; Poliwoda, H, 1993) |
| "The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5." | 2.67 | Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. ( Bueschen, A; Crawford, ED; Flanigan, RC; Kish, JA; Leimert, JT; Neefe, JR; Wolf, M, 1994) |
| "Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate." | 2.67 | Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. ( Fosså, SD; Haarstad, H; Jacobsen, AB; Risberg, T; Schjølseth, SA, 1994) |
| "A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy." | 2.67 | Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992) |
| "Responses in metastatic renal cell carcinoma appear confined to a favorable subset of patients." | 2.66 | Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. ( Dexeus, FH; Finn, L; Logothetis, CJ; Sella, A, 1989) |
| " Future strategies should focus on investigating the immunomodulatory effects of chemotherapy in conjunction with TroVax, understanding the optimal dosing and schedule of the combination, and examining potential predictive biomarkers to determine which patients may benefit from immunotherapy from those who do not." | 2.50 | TroVax in colorectal cancer. ( Cen, P; Rowe, J, 2014) |
| "Metastatic renal cell carcinoma has a poor prognosis." | 2.43 | Immunotherapy in metastatic renal cell carcinoma. ( Bachmann, A; Haseke, N; Rohrmann, K; Siebels, M; Staehler, M; Stief, CG, 2005) |
| "Renal cell cancer is still a challenge not only concerning operative techniques (nephron-sparing techniques, established minimally-invasive techniques, such as laparoscopy, and experimental minimally-invasive techniques, such as cryoablation, radiofrequency ablation and others), but also with regard to the impact of systemic (immuno)therapy." | 2.42 | [Immunotherapy of renal cell carcinoma: results from current phase-III-trials]. ( Doehn, C; Jocham, D, 2004) |
| "Treatment of metastatic renal cell carcinoma (RCC) remains unsatisfactory." | 2.41 | Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. ( Bukowski, RM, 2000) |
| "In urinary bladder cancer, the combination chemotherapy with 5-FU and low-dose CDDP has been used as a radiosensitizer." | 2.40 | [Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors]. ( Fujinami, K; Kubota, Y, 1999) |
| "The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients." | 2.38 | [Interferon-alpha therapy in hypernephroma]. ( Sagaster, KP, 1993) |
| "Clear cell renal cell carcinoma (ccRCC) has poor clinical outcomes and necessitates new treatment options." | 1.91 | Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA. ( Liu, D; Xu, M; Zhou, G, 2023) |
| "However, in clear cell renal cell carcinoma (ccRCC), p53 is rarely mutated, yet the tumors remain highly insensitive to the conventional chemotherapeutic drugs." | 1.46 | Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation. ( Cheng, Y; Ge, W; Han, Z; Hu, Y; Jiang, Q; Jiang, S; Li, H; Li, Z; Liu, T; Wang, X; Wu, Q; Wu, X; Yu, M; Yuan, J; Zhang, C; Zhao, K; Zhu, Y, 2017) |
| "BACKGROUND Renal cell carcinoma (RCC) is among the most common malignant cancers of males worldwide." | 1.46 | Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models. ( Cui, S, 2017) |
| "Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome." | 1.46 | Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. ( Aubert, S; Cauffiez, C; Gaudelot, K; Gibier, JB; Glowacki, F; Gnemmi, V; Hémon, B; Leroy, X; Perrais, M; Pottier, N; Van Seuningen, I, 2017) |
| "Despite several therapeutic options renal cell carcinoma is associated with a poor clinical outcome." | 1.42 | Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. ( Choi, EK; Hwang, JJ; Jeong, IG; Kang, JS; Kim, CS; Kim, MJ; Lee, JS; Lee, JY; Park, SE; Ro, S; Yi, HJ; Yun, J, 2015) |
| "However, its roles in clear cell renal cell carcinoma (RCC) are unclear." | 1.37 | The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. ( Cao, K; Chen, J; Guo, S; Huang, B; Li, X; Mao, X; Mo, C; Pan, J; Qiu, S; Wang, Z; Zhuang, J, 2011) |
| " We then examined the antitumor effect of IAB-1 in combination with anticancer drugs against RCC." | 1.35 | Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. ( Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J, 2008) |
| "An involvement of Pak1 in renal cell carcinoma (RCC), which remains highly refractory to chemotherapy and radiotherapy, remains to be investigated." | 1.34 | Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. ( Ambrose, M; Barry, OP; Casey, G; Houston, A; O'Sullivan, GC; Tangney, M, 2007) |
| "Treatment of renal cell carcinoma (RCC) is limited by its resistance to conventional chemotherapies." | 1.33 | Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. ( Davidson, K; Gobe, GC; Johnson, DW; Li, J; Nicol, D; Pat, BK; Percy, C; Rennick, AJ, 2005) |
| "The results suggest that adenovirus-mediated IL-12 gene transfer combined with Ad." | 1.33 | Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. ( Cho, WK; Hwang, KS; Im, DS; Kim, S; Yoo, J; Yun, HJ, 2005) |
| "The NC65 renal cell carcinoma line was used as a target." | 1.33 | Gene therapy with TRAIL against renal cell carcinoma. ( Hongo, F; Kawauchi, A; Kimura, Y; Matsubara, H; Miki, T; Mizutani, Y; Nakanishi, H; Sakata, T; Tamura, T; Ushijima, S, 2006) |
| "Renal cell carcinoma is an uncommon tumor in adults." | 1.33 | Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma. ( Alcaide-García, J; Alés-Díaz, I; Benavides-Orgaz, M; Cobo-Dols, M; Gil-Calle, S; Gutiérrez-Calderón, V; Montesa-Pino, A; Villar-Chamorro, E, 2006) |
| "However, long-term survival of cytokine-treated, advanced renal cell carcinoma (RCC) patients remains a rare event and, thus, emphasizes the need for further investigations toward more effective therapies." | 1.33 | Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. ( Atzpodien, J; Reitz, M, 2005) |
| "Metastatic renal cell cancer has a poor prognosis and survival." | 1.33 | Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. ( Goldstein, D; Marx, G; Taylor, J, 2005) |
| "Conventional therapy for renal cell carcinoma (RCC) using interferon (IFN) has shown limited antitumor action." | 1.32 | Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma. ( Ishii, T; Marumo, K, 2004) |
| "5-Fluorouracil (5-FU) is an anticancer agent clinically used against various cancers including renal cell carcinoma (RCC)." | 1.32 | Significance of thymidylate synthase activity in renal cell carcinoma. ( Fukushima, M; Miki, T; Mizutani, Y; Nakao, M; Nonomura, M; Wada, H; Yoshida, O, 2003) |
| " These data indicate that rejection of primary and metastatic tumors can be achieved after intratumoral delivery of a nonviral IL-2 gene therapy, and is increased in combination with systemic delivery of a conventional chemotherapeutic agent." | 1.31 | Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil. ( Batten, TL; Bishop, JS; Matar, M; Muller, S; Munger, WE; Pericle, F; Quezada, A; Thull, NM, 2000) |
| "Isoliquiritigenin is a chalcone isolated from licorice and shallots." | 1.31 | Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002) |
| "Conventional therapy for renal cell carcinoma using interferon (IFN) has shown limited antitumor action." | 1.30 | Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma. ( Marumo, K; Murai, M; Oya, M, 1997) |
| "The protocol for renal cell carcinoma consisted of combined chemotherapy with continuous infusion of 5-FU 250 mg/m2/day and CDDP 3 mg/m2/day in 2 weeks for 1 cycles (4 weeks)." | 1.30 | [Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma]. ( Hata, M; Ono, S; Ota, N; Otsuka, A, 1997) |
| "Immunotherapy management for advanced renal carcinoma has awaken a growing interest over the last few years." | 1.30 | [Immunotherapeutic treatment for metastatic renal carcinoma]. ( García Bueno, JM; Gutiérrez Sanz-Gadea, C; Hidalgo Pardo, F; Losada González, GP; Mus Malleu, A; Ozonas Moragues, M; Rebassa Llull, MJ, 1998) |
| "In patients with advanced metastatic renal cell carcinoma (RCC) seen at a single institution, the toxicity and long-term clinical effects of a combination therapy with recombinant interleukin-2 (rIL-2), recombinant interferon-alpha2 (rIFN-alpha2) and 5-fluorouracil (5-FU) were evaluated." | 1.30 | Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. ( Allhoff, EP; Gruss, A; Reiher, F; Samland, D; Schmidt, U; Steinbach, F, 1999) |
| " In conclusion, we describe the predictive value of the number of lymphocytes from peripheral blood for the efficiency of IL-2/IFN-alpha-2b therapy in combination with 5-FU in patients with metastatic renal cell carcinoma." | 1.29 | Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. ( Göhring, B; Heynemann, H; Langner, J; Rebmann, U; Riemann, D; Schabel, J, 1996) |
| "In metastatic renal cell carcinoma, most conventional antineoplastic drugs have yielded no or little efficacy." | 1.29 | Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma. ( Atzpodien, J; Lopez Hanninen, E; Poliwoda, H, 1995) |
| "Three patients with lung metastases of renal cell carcinoma (RCC) were treated with a combination of interferon-alpha, leucovorin and 5-fluorouracil." | 1.29 | [Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin]. ( Demura, T; Hirakawa, K; Hirano, T; Ohashi, N; Sindoh, J; Tabata, T; Togashi, M, 1996) |
| "Renal cell carcinoma has been considered a tumor highly insensitive to conventional chemotherapy because of its multivariate biological potential, delayed manifestation of clinical symptoms and the lack of systematic investigation." | 1.29 | [Current status of chemotherapy for renal cell carcinoma]. ( Kato, T; Sato, K, 1994) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i." | 1.28 | Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer. ( Ferrari, V; Marini, G; Marpicati, P; Montini, E; Simoncini, E; Zaniboni, A, 1989) |
| "A case of renal cell carcinoma with multiple lung metastases successfully treated with interferon (IFN) following nephrectomy is reported." | 1.28 | [A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta]. ( Horie, M; Kawada, Y; Kobayashi, S; Komeda, H; Kuriyama, M; Takahashi, Y; Yamada, S, 1989) |
| "A metastatic renal cell carcinoma was found on the pelvic peritoneum and characteristic renal cancer cells were identified in the ascitic fluid." | 1.27 | [Synchronous double cancers in the ovary and kidney--a case report]. ( Fujiwara, A; Katsube, Y; Myoga, H; Nogawa, T; Ohta, S; Shigemasa, K; Shinko, Y; Tamaki, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (3.30) | 18.7374 |
| 1990's | 59 (27.83) | 18.2507 |
| 2000's | 101 (47.64) | 29.6817 |
| 2010's | 43 (20.28) | 24.3611 |
| 2020's | 2 (0.94) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, D | 1 |
| Zhou, G | 1 |
| Xu, M | 1 |
| Cao, J | 1 |
| Sun, X | 1 |
| Zhang, X | 2 |
| Chen, D | 1 |
| Tsujino, T | 1 |
| Takahara, K | 1 |
| Matsunaga, T | 1 |
| Yoshikawa, Y | 1 |
| Takai, T | 1 |
| Uchimoto, T | 1 |
| Saito, K | 2 |
| Tanda, N | 1 |
| Hirano, H | 1 |
| Nomi, H | 1 |
| Ibuki, N | 1 |
| Inamoto, T | 1 |
| Azuma, H | 1 |
| Wang, X | 4 |
| Cheng, Y | 2 |
| Zhu, Y | 1 |
| Li, H | 2 |
| Ge, W | 2 |
| Wu, X | 1 |
| Zhao, K | 2 |
| Yuan, J | 1 |
| Li, Z | 1 |
| Jiang, S | 1 |
| Han, Z | 1 |
| Jiang, Q | 1 |
| Wu, Q | 1 |
| Liu, T | 1 |
| Zhang, C | 2 |
| Yu, M | 2 |
| Hu, Y | 2 |
| Cui, S | 1 |
| Gaudelot, K | 1 |
| Gibier, JB | 1 |
| Pottier, N | 1 |
| Hémon, B | 1 |
| Van Seuningen, I | 1 |
| Glowacki, F | 1 |
| Leroy, X | 1 |
| Cauffiez, C | 1 |
| Gnemmi, V | 1 |
| Aubert, S | 1 |
| Perrais, M | 1 |
| Hida, K | 1 |
| Maishi, N | 1 |
| Akiyama, K | 1 |
| Ohmura-Kakutani, H | 1 |
| Torii, C | 1 |
| Ohga, N | 1 |
| Osawa, T | 1 |
| Kikuchi, H | 1 |
| Morimoto, H | 1 |
| Morimoto, M | 1 |
| Shindoh, M | 1 |
| Shinohara, N | 1 |
| Hida, Y | 1 |
| Cai, A | 1 |
| Zhang, Y | 2 |
| Han, F | 1 |
| Zheng, W | 1 |
| Zhou, CY | 1 |
| Zhu, XQ | 1 |
| Wang, XJ | 1 |
| Li, ZY | 1 |
| Chen, XC | 1 |
| Chen, F | 1 |
| Che, XY | 1 |
| Xie, X | 1 |
| Wei, R | 1 |
| He, D | 1 |
| Rustum, YM | 1 |
| Chintala, S | 1 |
| Durrani, FA | 1 |
| Bhattacharya, A | 1 |
| Lin, JA | 1 |
| Fang, SU | 1 |
| Su, CL | 1 |
| Hsiao, CJ | 1 |
| Chang, CC | 1 |
| Lin, YF | 1 |
| Cheng, CW | 1 |
| Conter, HJ | 1 |
| Lim, ZD | 2 |
| Ng, CS | 2 |
| Millikan, RE | 2 |
| Tannir, NM | 5 |
| Chen, B | 1 |
| Duan, L | 1 |
| Yin, G | 1 |
| Tan, J | 1 |
| Jiang, X | 1 |
| Aitchison, M | 2 |
| Bray, CA | 1 |
| Van Poppel, H | 1 |
| Sylvester, R | 2 |
| Graham, J | 1 |
| Innes, C | 1 |
| McMahon, L | 1 |
| Vasey, PA | 1 |
| Bellmunt, J | 2 |
| Suarez, C | 2 |
| Gallardo, E | 1 |
| Rodon, J | 1 |
| Pons, F | 1 |
| Bonfill, T | 1 |
| Beltran, M | 1 |
| Moya, I | 1 |
| Galtes, S | 1 |
| Albanell, J | 2 |
| Carles, J | 3 |
| Hagos, Y | 1 |
| Wegner, W | 1 |
| Kuehne, A | 1 |
| Floerl, S | 1 |
| Marada, VV | 1 |
| Burckhardt, G | 1 |
| Henjakovic, M | 1 |
| Donini, M | 2 |
| Buti, S | 3 |
| Lazzarelli, S | 2 |
| Bozzetti, R | 1 |
| Rivoltini, L | 1 |
| Camisaschi, C | 1 |
| Castelli, C | 1 |
| Bearz, A | 1 |
| Simonelli, C | 2 |
| Lo Re, G | 1 |
| Mattioli, R | 2 |
| Caminiti, C | 2 |
| Passalacqua, R | 3 |
| Kim, MJ | 1 |
| Lee, JS | 2 |
| Park, SE | 1 |
| Yi, HJ | 1 |
| Jeong, IG | 2 |
| Kang, JS | 1 |
| Yun, J | 1 |
| Lee, JY | 1 |
| Ro, S | 1 |
| Choi, EK | 1 |
| Hwang, JJ | 1 |
| Kim, CS | 1 |
| Rowe, J | 1 |
| Cen, P | 1 |
| Soerensen, AV | 1 |
| Donskov, F | 1 |
| Kjellberg, J | 1 |
| Ibsen, R | 1 |
| Hermann, GG | 1 |
| Jensen, NV | 1 |
| Fode, K | 1 |
| Geertsen, PF | 1 |
| Peng, J | 1 |
| Mo, R | 1 |
| Ma, J | 1 |
| Fan, J | 1 |
| Al-Hameed, FM | 1 |
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Thall, PF | 1 |
| Wooten, L | 1 |
| Siefker-Radtke, A | 1 |
| Mathew, P | 1 |
| Pagliaro, L | 1 |
| Wood, C | 1 |
| Jonasch, E | 4 |
| Marur, S | 1 |
| Eliason, J | 1 |
| Heilbrun, LK | 1 |
| Dickow, B | 1 |
| Smith, DW | 1 |
| Baranowski, K | 1 |
| Alhasan, S | 1 |
| Vaishampayan, U | 1 |
| Yamamoto, K | 3 |
| Mizutani, Y | 8 |
| Nakanishi, H | 5 |
| Fujiwara, J | 1 |
| Ishida, H | 1 |
| Toiyama, D | 1 |
| Abe, K | 1 |
| Hayashi, I | 1 |
| Okada, K | 1 |
| Kawauchi, A | 2 |
| Mizuno, M | 1 |
| Yoshida, J | 1 |
| Miki, T | 6 |
| Moriya, F | 1 |
| Ogasawara, S | 1 |
| Basaki, Y | 3 |
| Akiba, J | 1 |
| Kojiro, S | 1 |
| Fukahori, S | 1 |
| Ishizaki, H | 1 |
| Nishida, N | 1 |
| Matsuoka, K | 1 |
| Kojiro, M | 1 |
| Kuwano, M | 1 |
| Yano, H | 1 |
| George, S | 1 |
| Dreicer, R | 1 |
| Au, JJ | 1 |
| Shen, T | 1 |
| Rini, BI | 5 |
| Roman, S | 1 |
| Cooney, MM | 1 |
| Mekhail, T | 1 |
| Elson, P | 2 |
| Wientjes, GM | 1 |
| Ganapathi, R | 1 |
| Bukowski, RM | 3 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 1 |
| Daliani, DD | 1 |
| Papandreou, CN | 1 |
| Swisher, S | 1 |
| Wood, CG | 1 |
| Swanson, DA | 2 |
| Logothetis, CJ | 5 |
| Soga, N | 1 |
| Yamada, Y | 4 |
| Nishikawa, K | 1 |
| Hasegawa, Y | 1 |
| Kise, H | 1 |
| Arima, K | 1 |
| Sugimura, Y | 1 |
| Van Veldhuizen, PJ | 1 |
| Hussey, M | 1 |
| Lara, PN | 1 |
| Mack, PC | 1 |
| Gandour-Edwards, R | 1 |
| Clark, JI | 1 |
| Lange, MK | 1 |
| Crawford, DE | 1 |
| Yuen, JS | 1 |
| Akkaya, E | 1 |
| Wang, Y | 1 |
| Takiguchi, M | 1 |
| Peak, S | 1 |
| Sullivan, M | 1 |
| Protheroe, AS | 1 |
| Macaulay, VM | 1 |
| Kraemer, A | 1 |
| Hauser, S | 2 |
| Kim, Y | 1 |
| Gorschlüter, M | 1 |
| Müller, SC | 3 |
| Brossart, P | 1 |
| Schmidt-Wolf, IG | 1 |
| Sunela, KL | 1 |
| Koskinen, S | 1 |
| Kellokumpu-Lehtinen, PL | 1 |
| Liu, JZ | 1 |
| Chen, SG | 1 |
| Zhang, B | 1 |
| Wang, CB | 1 |
| Zhao, XW | 1 |
| Li, GY | 1 |
| Wang, LX | 1 |
| Serrano, C | 1 |
| Andreu, J | 1 |
| Tai, CJ | 1 |
| Gore, ME | 3 |
| Griffin, CL | 1 |
| Hancock, B | 1 |
| Patel, PM | 1 |
| Pyle, L | 2 |
| James, N | 1 |
| Oliver, RT | 2 |
| Mardiak, J | 1 |
| Hussain, T | 1 |
| Parmar, MK | 1 |
| Royston, P | 1 |
| Mulders, PF | 2 |
| Trigo, JM | 1 |
| Calvo, E | 1 |
| Pérez-Gracia, JL | 1 |
| Rubió, J | 1 |
| Virizuela, JA | 1 |
| López, R | 1 |
| Lázaro, M | 1 |
| Escudier, B | 5 |
| Ravaud, A | 4 |
| Grossgoupil, M | 1 |
| Goodsaid, FM | 1 |
| Amur, S | 1 |
| Aubrecht, J | 1 |
| Burczynski, ME | 1 |
| Carl, K | 1 |
| Catalano, J | 1 |
| Charlab, R | 1 |
| Close, S | 1 |
| Cornu-Artis, C | 1 |
| Essioux, L | 1 |
| Fornace, AJ | 1 |
| Hinman, L | 1 |
| Hong, H | 1 |
| Hunt, I | 1 |
| Jacobson-Kram, D | 1 |
| Jawaid, A | 1 |
| Laurie, D | 1 |
| Lesko, L | 1 |
| Li, HH | 1 |
| Lindpaintner, K | 1 |
| Mayne, J | 1 |
| Morrow, P | 1 |
| Papaluca-Amati, M | 1 |
| Robison, TW | 1 |
| Roth, J | 1 |
| Schuppe-Koistinen, I | 1 |
| Shi, L | 1 |
| Spleiss, O | 1 |
| Tong, W | 1 |
| Truter, SL | 1 |
| Vonderscher, J | 1 |
| Westelinck, A | 1 |
| Zhang, L | 1 |
| Zineh, I | 1 |
| Chiesa, MD | 2 |
| Re, GL | 1 |
| Lheshi, A | 1 |
| Simon, S | 1 |
| Mazza, G | 1 |
| Zhong, Y | 1 |
| Guan, K | 1 |
| Guo, S | 2 |
| Zhou, C | 1 |
| Wang, D | 1 |
| Ma, W | 1 |
| Li, C | 1 |
| Zhang, S | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 1 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Richey, SL | 1 |
| Ng, C | 1 |
| Bierer, S | 2 |
| Hoffmeister, I | 1 |
| Gerss, J | 1 |
| Herrmann, E | 2 |
| Wülfing, C | 2 |
| Sibrowski, W | 1 |
| Hertle, L | 3 |
| Kelsch, R | 1 |
| Lal, LS | 1 |
| Atkinson, BJ | 1 |
| Byfield, SD | 1 |
| Miller, LA | 1 |
| Pagliaro, LC | 1 |
| Feng, C | 1 |
| Porta, C | 1 |
| Paglino, C | 1 |
| Tsimafeyeu, I | 1 |
| Demidov, L | 1 |
| Kharkevich, G | 1 |
| Petenko, N | 1 |
| Galchenko, V | 1 |
| Sinelnikov, I | 1 |
| Naidzionak, U | 1 |
| Takeuchi, A | 1 |
| Shiota, M | 1 |
| Tatsugami, K | 1 |
| Yokomizo, A | 1 |
| Eto, M | 1 |
| Inokuchi, J | 1 |
| Kuroiwa, K | 1 |
| Kiyoshima, K | 1 |
| Naito, S | 1 |
| Chang, HR | 1 |
| Chen, PN | 1 |
| Yang, SF | 1 |
| Sun, YS | 1 |
| Wu, SW | 1 |
| Hung, TW | 1 |
| Lian, JD | 1 |
| Chu, SC | 1 |
| Hsieh, YS | 1 |
| Walter, B | 1 |
| Schrettenbrunner, I | 1 |
| Vogelhuber, M | 1 |
| Grassinger, J | 1 |
| Bross, K | 1 |
| Wilke, J | 1 |
| Suedhoff, T | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Rogenhofer, S | 1 |
| Andreesen, R | 1 |
| Reichle, A | 1 |
| Gilles, R | 1 |
| de Geus-Oei, LF | 1 |
| Oyen, WJ | 1 |
| Huang, B | 1 |
| Cao, K | 1 |
| Li, X | 1 |
| Mao, X | 1 |
| Wang, Z | 1 |
| Zhuang, J | 1 |
| Pan, J | 1 |
| Mo, C | 1 |
| Chen, J | 1 |
| Qiu, S | 1 |
| Hughes, C | 1 |
| Brown, MD | 1 |
| Clarke, NW | 1 |
| Flower, KR | 1 |
| Gardner, P | 1 |
| Bronchud, MH | 1 |
| Castillo, S | 1 |
| Escriva de Romaní, S | 1 |
| Mourelo, S | 1 |
| Fernández, A | 1 |
| Baena, C | 1 |
| Murillo, J | 1 |
| Julia, JC | 1 |
| Esquius, J | 1 |
| Romero, R | 1 |
| Andreu, X | 1 |
| Ryan, CW | 2 |
| Vogelzang, NJ | 7 |
| Stadler, WM | 9 |
| Atzpodien, J | 14 |
| Hoffmann, R | 2 |
| Franzke, M | 1 |
| Stief, C | 1 |
| Wandert, T | 5 |
| Reitz, M | 7 |
| Desai, AA | 2 |
| Ansari, R | 1 |
| Krauss, S | 1 |
| Gez, E | 3 |
| Rubinov, R | 3 |
| Gaitini, D | 2 |
| Meretyk, S | 2 |
| Best, LA | 2 |
| Native, O | 2 |
| Stein, A | 3 |
| Erlich, N | 1 |
| Beny, A | 1 |
| Zidan, J | 1 |
| Haim, N | 2 |
| Kuten, A | 3 |
| Bennouna, J | 1 |
| Delva, R | 1 |
| Gomez, F | 3 |
| Lesimple, T | 3 |
| Geoffrois, L | 2 |
| Linassier, C | 2 |
| Chevreau, C | 2 |
| Douillard, JY | 3 |
| Négrier, S | 3 |
| Hirano, Y | 3 |
| Takayama, T | 3 |
| Kageyama, S | 2 |
| Ushiyama, T | 3 |
| Suzuki, K | 4 |
| Fujita, K | 4 |
| Vozianov, AF | 1 |
| Zak, KP | 1 |
| Zubko, VI | 1 |
| Romanenko, AM | 1 |
| Klimenko, IA | 1 |
| Babich, VM | 1 |
| Kushneruk, IuI | 1 |
| Shcherbak, AIu | 1 |
| Bazalitskaia, SV | 1 |
| Gruzov, MA | 1 |
| Wada, H | 3 |
| Yoshida, O | 5 |
| Fukushima, M | 4 |
| Nonomura, M | 1 |
| Nakao, M | 2 |
| Roigas, J | 3 |
| Deger, S | 1 |
| Taymoorian, K | 1 |
| Wille, AH | 1 |
| Johannsen, M | 1 |
| Türk, I | 1 |
| Schnorr, D | 1 |
| Loening, SA | 2 |
| Amato, RJ | 6 |
| Huo, D | 1 |
| George, C | 1 |
| Yang, X | 1 |
| Karrison, T | 1 |
| Zimmerman, TM | 1 |
| Wenzel, C | 2 |
| Locker, GJ | 2 |
| Bartsch, R | 1 |
| Pluschnig, U | 1 |
| Mader, R | 2 |
| Hussian, D | 1 |
| Kramer, G | 2 |
| Marberger, M | 2 |
| Lintner, C | 1 |
| Rauchenwald, M | 2 |
| Zielinski, CC | 2 |
| Steger, GG | 2 |
| Trufflandier, N | 1 |
| Ferrière, JM | 1 |
| Debled, M | 1 |
| Palussière, J | 1 |
| Cany, L | 1 |
| Gaston, R | 1 |
| Mathoulin-Pélissier, S | 1 |
| Bui, BN | 1 |
| Kirchner, H | 8 |
| Jonas, U | 2 |
| Bergmann, L | 1 |
| Schott, H | 2 |
| Heynemann, H | 4 |
| Fornara, P | 3 |
| Bodenstein, H | 1 |
| Pomer, S | 1 |
| Metzner, B | 3 |
| Rebmann, U | 4 |
| Oberneder, R | 1 |
| Siebels, M | 3 |
| Puchberger, T | 1 |
| Rathmell, WK | 1 |
| Malkowicz, SB | 1 |
| Holroyde, C | 1 |
| Luginbuhl, W | 1 |
| Vaughn, DJ | 1 |
| O'Brien, MF | 1 |
| Rea, D | 1 |
| Rogers, E | 1 |
| Bredin, H | 1 |
| Butler, M | 1 |
| Grainger, R | 1 |
| McDermott, TE | 1 |
| Mullins, G | 1 |
| O'Brien, A | 1 |
| Twomey, A | 1 |
| Thornhill, J | 1 |
| Wu, XX | 3 |
| Ogawa, O | 5 |
| Kakehi, Y | 4 |
| Doehn, C | 2 |
| Jocham, D | 2 |
| May, M | 1 |
| Helke, C | 1 |
| Bock, M | 1 |
| Hoschke, B | 1 |
| Rexer, H | 1 |
| Waters, JS | 1 |
| Moss, C | 1 |
| James, M | 1 |
| Hackett, S | 1 |
| A'hern, R | 1 |
| Gore, M | 1 |
| Eisen, T | 2 |
| Ishii, T | 1 |
| Marumo, K | 3 |
| Anderson, DA | 1 |
| Woltman, ML | 1 |
| Kovach, G | 1 |
| Konety, BR | 1 |
| Ikemoto, S | 1 |
| Sugimura, K | 1 |
| Yoshida, N | 1 |
| Kuratsukuri, K | 1 |
| Wada, S | 1 |
| Nakatani, T | 2 |
| Weinberg, V | 1 |
| Small, EJ | 2 |
| Marx, G | 1 |
| Taylor, J | 1 |
| Goldstein, D | 1 |
| Wang, HJ | 1 |
| Chen, HX | 1 |
| Li, HZ | 1 |
| Davidson, K | 1 |
| Percy, C | 1 |
| Rennick, AJ | 1 |
| Pat, BK | 1 |
| Li, J | 1 |
| Nicol, D | 1 |
| Johnson, DW | 1 |
| Gobe, GC | 1 |
| Schmitt, E | 1 |
| Gertenbach, U | 2 |
| Maskow, A | 1 |
| Ecke, M | 1 |
| Wöltjen, HH | 1 |
| Jentsch, H | 1 |
| Wieland, W | 1 |
| Rohrmann, K | 1 |
| Staehler, M | 1 |
| Haseke, N | 1 |
| Bachmann, A | 1 |
| Stief, CG | 1 |
| Brinkmann, OA | 2 |
| Bruns, F | 1 |
| Gosheger, G | 1 |
| Micke, O | 1 |
| Hwang, KS | 1 |
| Cho, WK | 1 |
| Yoo, J | 1 |
| Yun, HJ | 1 |
| Kim, S | 1 |
| Im, DS | 1 |
| Dilhuydy, MS | 1 |
| Rawat, A | 1 |
| Hong, SK | 2 |
| Kwak, C | 2 |
| Lee, SE | 2 |
| Byun, SS | 1 |
| Gill, MC | 1 |
| Chang, IH | 1 |
| Kim, YJ | 1 |
| Cobo-Dols, M | 1 |
| Alés-Díaz, I | 1 |
| Villar-Chamorro, E | 1 |
| Gil-Calle, S | 1 |
| Alcaide-García, J | 1 |
| Montesa-Pino, A | 1 |
| Gutiérrez-Calderón, V | 1 |
| Benavides-Orgaz, M | 1 |
| Soder, M | 1 |
| Raschke, R | 1 |
| Salm, S | 1 |
| Schwindl, B | 1 |
| Leiber, C | 1 |
| Huland, E | 1 |
| Heinzer, H | 1 |
| Siemer, S | 1 |
| Halabi, S | 1 |
| Rini, B | 1 |
| Ernstoff, MS | 1 |
| Davila, E | 1 |
| Picus, J | 1 |
| Barrier, R | 1 |
| Matsubara, H | 1 |
| Hongo, F | 1 |
| Kimura, Y | 1 |
| Ushijima, S | 1 |
| Tamura, T | 1 |
| Sakata, T | 1 |
| Bode, ME | 1 |
| Köpke, T | 1 |
| Bögemann, M | 1 |
| Varan, A | 1 |
| Akyuz, C | 1 |
| Sari, N | 1 |
| Buyukpamukçu, N | 1 |
| Cağlar, M | 1 |
| Buyukpamukçu, M | 1 |
| Shang, D | 2 |
| Ito, N | 2 |
| Watanabe, J | 1 |
| Awakura, Y | 1 |
| Nishiyama, H | 1 |
| Kamoto, T | 2 |
| Mashiach, T | 1 |
| Quinn, DI | 1 |
| Bukowski, R | 1 |
| Poiesz, B | 1 |
| Kardinal, CG | 1 |
| Lewis, N | 1 |
| Makalinao, A | 1 |
| Murray, P | 1 |
| Torti, FM | 1 |
| Petrioli, R | 1 |
| Paolelli, L | 1 |
| Francini, E | 1 |
| Marsili, S | 1 |
| Pascucci, A | 1 |
| Sciandivasci, A | 1 |
| de Rubertis, G | 1 |
| Barbanti, G | 1 |
| Manganelli, A | 1 |
| Salvestrini, F | 1 |
| Francini, G | 1 |
| O'Sullivan, GC | 1 |
| Tangney, M | 1 |
| Casey, G | 1 |
| Ambrose, M | 1 |
| Houston, A | 1 |
| Barry, OP | 1 |
| Khan, M | 1 |
| Merseburger, AS | 1 |
| Kuczyk, MA | 1 |
| Brighenti, M | 1 |
| Bongiovanni, C | 1 |
| Buzio, C | 1 |
| Alberici, F | 1 |
| Han, KS | 1 |
| Joung, JY | 1 |
| Choi, WS | 1 |
| Hwang, SS | 1 |
| Yang, SO | 1 |
| Seo, HK | 1 |
| Chung, J | 1 |
| Lee, KH | 1 |
| Kobayashi, M | 2 |
| Nakano, K | 1 |
| Ikeda, H | 1 |
| Nukui, A | 1 |
| Sugaya, Y | 1 |
| Yuzawa, M | 1 |
| Morita, T | 4 |
| Ju, SA | 1 |
| Cheon, SH | 1 |
| Park, SM | 1 |
| Tam, NQ | 1 |
| Kim, YM | 1 |
| An, WG | 1 |
| Kim, BS | 1 |
| Mohammad, T | 1 |
| Satomi, Y | 2 |
| Senga, Y | 1 |
| Fukuda, M | 1 |
| Nakahashi, M | 1 |
| Ohshima, H | 1 |
| Furuhata, A | 1 |
| Lopez Hänninen, E | 3 |
| Duensing, S | 1 |
| Franzke, A | 4 |
| Buer, J | 3 |
| Probst, M | 1 |
| Anton, P | 1 |
| Poliwoda, H | 4 |
| Ueno, NT | 1 |
| Zukiwski, AA | 2 |
| Imai, T | 2 |
| Katagiri, A | 2 |
| Tomita, Y | 3 |
| Noguchi, S | 1 |
| Shuin, T | 1 |
| Kubota, Y | 2 |
| Masuda, M | 1 |
| Yao, M | 1 |
| Hosaka, M | 1 |
| Sella, A | 6 |
| Kilbourn, RG | 1 |
| Gray, I | 1 |
| Finn, L | 2 |
| Ellerhorst, J | 2 |
| Kimura, M | 1 |
| Saitoh, K | 1 |
| Sato, S | 1 |
| Kish, JA | 1 |
| Wolf, M | 1 |
| Crawford, ED | 2 |
| Leimert, JT | 1 |
| Bueschen, A | 1 |
| Neefe, JR | 1 |
| Flanigan, RC | 3 |
| Haarstad, H | 1 |
| Jacobsen, AB | 1 |
| Schjølseth, SA | 1 |
| Risberg, T | 1 |
| Fosså, SD | 1 |
| Hänninen, EL | 2 |
| Deckert, M | 2 |
| Fenner, M | 2 |
| Sagaster, KP | 1 |
| Körfer, A | 1 |
| Menzel, T | 1 |
| Kato, T | 1 |
| Sato, K | 1 |
| Puduvalli, VK | 1 |
| Austin, SG | 1 |
| Forman, AD | 1 |
| Hofmockel, G | 2 |
| Langer, W | 2 |
| Theiss, M | 2 |
| Gruss, A | 3 |
| Frohmüller, HG | 1 |
| Togashi, M | 1 |
| Tabata, T | 1 |
| Hirakawa, K | 1 |
| Ohashi, N | 1 |
| Sindoh, J | 1 |
| Hirano, T | 1 |
| Demura, T | 1 |
| Elias, L | 3 |
| Blumenstein, BA | 1 |
| Kish, J | 1 |
| Wade, JL | 2 |
| Lowe, BA | 1 |
| Goodwin, JW | 1 |
| Gutman, M | 1 |
| Abu-Abid, S | 1 |
| Sorkine, P | 1 |
| Inbar, M | 1 |
| Lev, D | 1 |
| Chen, Z | 1 |
| Oron, D | 1 |
| Chaitchik, S | 1 |
| Klausner, JM | 1 |
| Fujinami, K | 2 |
| Ikeda, I | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| Göhring, B | 1 |
| Riemann, D | 1 |
| Schabel, J | 1 |
| Langner, J | 1 |
| Frohmüller, H | 1 |
| Oya, M | 1 |
| Murai, M | 1 |
| Banks, RE | 1 |
| Forbes, MA | 1 |
| Hallam, S | 1 |
| Jenkins, A | 1 |
| Wadhwa, M | 1 |
| Dilger, P | 1 |
| Meager, A | 1 |
| Thorpe, R | 1 |
| Bowmer, CJ | 1 |
| Joffe, JK | 1 |
| Patel, P | 1 |
| Johnson, PW | 1 |
| Selby, PJ | 1 |
| Thiounn, N | 1 |
| Pages, F | 1 |
| Flam, T | 1 |
| Tartour, E | 1 |
| Mosseri, V | 1 |
| Zerbib, M | 1 |
| Beuzeboc, P | 1 |
| Deneux, L | 1 |
| Fridman, WH | 1 |
| Debré, B | 1 |
| Loyer, E | 1 |
| David, C | 1 |
| Breul, J | 1 |
| Tief, G | 1 |
| Hartung, R | 1 |
| Ellerhorst, JA | 1 |
| Tu, SM | 1 |
| Finn, LD | 1 |
| Banks, M | 1 |
| Gebrosky, NP | 1 |
| Koukol, S | 1 |
| Nseyo, UO | 1 |
| Carpenter, C | 1 |
| Lamm, DL | 1 |
| Otsuka, A | 1 |
| Ono, S | 1 |
| Hata, M | 1 |
| Ota, N | 1 |
| Figlin, R | 1 |
| Gitlitz, B | 1 |
| Franklin, J | 1 |
| Dorey, F | 1 |
| Moldawer, N | 1 |
| Rausch, J | 1 |
| deKernion, J | 1 |
| Belldegrun, A | 1 |
| Hidalgo Pardo, F | 1 |
| Gutiérrez Sanz-Gadea, C | 1 |
| Rebassa Llull, MJ | 1 |
| García Bueno, JM | 1 |
| Mus Malleu, A | 1 |
| Losada González, GP | 1 |
| Ozonas Moragues, M | 1 |
| Kanematsu, A | 1 |
| Inoue, T | 1 |
| Nakano, T | 1 |
| Segawa, T | 1 |
| Hiura, M | 1 |
| Hashimura, T | 1 |
| Tourani, JM | 1 |
| Pfister, C | 1 |
| Berdah, JF | 1 |
| Benhammouda, A | 1 |
| Salze, P | 1 |
| Monnier, A | 1 |
| Paule, B | 1 |
| Guillet, P | 1 |
| Chretien, Y | 1 |
| Brewer, Y | 1 |
| Di Palma, M | 1 |
| Untereiner, M | 1 |
| Malaurie, E | 1 |
| Tadrist, Z | 1 |
| Pavlovitch, JM | 1 |
| Hauteville, D | 1 |
| Mejean, A | 1 |
| Azagury, M | 1 |
| Mayeur, D | 1 |
| Lucas, V | 1 |
| Krakowski, I | 1 |
| Larregain-Fournier, D | 1 |
| Abourachid, H | 1 |
| Andrieu, JM | 1 |
| Chastang, C | 1 |
| Audhuy, B | 1 |
| Caty, A | 2 |
| Ferrero, JM | 1 |
| Drevon, M | 1 |
| Creagan, ET | 1 |
| Veeder, MH | 1 |
| Suman, VJ | 1 |
| Burch, PA | 1 |
| Maples, WJ | 1 |
| Schaefer, PL | 1 |
| Pfeifle, DM | 1 |
| Dalton, RJ | 1 |
| Hatfield, AK | 1 |
| Poon, MA | 1 |
| Igarashi, T | 1 |
| Onishi, T | 1 |
| Aiba, K | 1 |
| Tsushima, T | 1 |
| Ozono, S | 1 |
| Terachi, T | 2 |
| Kawamura, J | 1 |
| Van Kuilenburg, AB | 1 |
| van Lenthe, H | 1 |
| Blom, MJ | 1 |
| Mul, EP | 1 |
| Van Gennip, AH | 1 |
| Samland, D | 1 |
| Steinbach, F | 1 |
| Reiher, F | 1 |
| Schmidt, U | 1 |
| Allhoff, EP | 1 |
| Binder, M | 1 |
| Mangalik, A | 1 |
| Clark, D | 1 |
| Morrison, B | 1 |
| Altobelli, KK | 1 |
| Smith, A | 1 |
| Mekori, T | 1 |
| Struminger, L | 1 |
| Nativ, O | 1 |
| Tippin, DB | 1 |
| Reeves, W | 1 |
| Tokue, A | 3 |
| Yonekura, K | 2 |
| Chikahisa, L | 2 |
| Okabe, S | 2 |
| Hashimoto, A | 2 |
| Miyadera, K | 2 |
| Wierzba, K | 2 |
| Nishiyama, M | 1 |
| Yamamoto, W | 1 |
| Park, JS | 1 |
| Okamoto, R | 1 |
| Hanaoka, H | 1 |
| Takano, H | 1 |
| Saito, N | 1 |
| Matsukawa, M | 1 |
| Shirasaka, T | 1 |
| Kurihara, M | 1 |
| van Herpen, CM | 1 |
| Jansen, RL | 1 |
| Kruit, WH | 1 |
| Hoekman, K | 1 |
| Groenewegen, G | 1 |
| Osanto, S | 1 |
| De Mulder, PH | 1 |
| Dumas, MC | 1 |
| Taber, DA | 1 |
| Lew, D | 1 |
| Figlin, RA | 1 |
| Thompson, ME | 1 |
| Triozzi, PL | 1 |
| Belt, RJ | 1 |
| Wood, DP | 1 |
| Rivkin, SE | 1 |
| David, E | 1 |
| Oevermann, K | 1 |
| Schrader, A | 1 |
| Patzelt, T | 2 |
| Bishop, JS | 1 |
| Thull, NM | 1 |
| Matar, M | 1 |
| Quezada, A | 1 |
| Munger, WE | 1 |
| Batten, TL | 1 |
| Muller, S | 1 |
| Pericle, F | 1 |
| Allen, MJ | 1 |
| Vaughan, M | 1 |
| Webb, A | 1 |
| Johnston, S | 1 |
| Savage, P | 1 |
| Bate, S | 1 |
| Moore, J | 1 |
| Ahern, R | 1 |
| Dutcher, JP | 1 |
| Logan, T | 1 |
| Gordon, M | 1 |
| Sosman, J | 1 |
| Weiss, G | 1 |
| Margolin, K | 1 |
| Plasse, T | 1 |
| Mier, J | 1 |
| Lotze, M | 1 |
| Clark, J | 1 |
| Atkins, M | 1 |
| Rossi, JF | 1 |
| Viens, P | 1 |
| Amato, R | 2 |
| Matsuzaki, A | 1 |
| Liu, JH | 1 |
| Yang, MH | 1 |
| Fan, FS | 1 |
| Yen, CC | 1 |
| Wang, WS | 1 |
| Chang, YH | 1 |
| Chen, KK | 1 |
| Chen, PM | 1 |
| Olencki, T | 1 |
| Peereboom, D | 1 |
| Wood, L | 1 |
| Budd, GT | 1 |
| Novick, A | 1 |
| Finke, J | 1 |
| McLain, D | 1 |
| Lu, J | 1 |
| Illiger, HJ | 1 |
| Ukena, D | 1 |
| Funke, PJ | 1 |
| Gramatzki, M | 1 |
| Jürgenson, S | 1 |
| Mani, S | 1 |
| Bertucci, D | 1 |
| Schilsky, RL | 1 |
| Ratain, MJ | 1 |
| Bonavida, B | 1 |
| Schmidinger, M | 1 |
| Probst-Kepper, M | 1 |
| Lindig, C | 1 |
| Framzle, M | 1 |
| Schrader, AJ | 1 |
| Ganser, A | 1 |
| Yanai, Y | 1 |
| Horie, S | 1 |
| Yamauchi, H | 1 |
| Ikegami, H | 1 |
| Kurimoto, M | 1 |
| Kitamura, T | 1 |
| George, CM | 1 |
| Geoffroy, FJ | 1 |
| Kollipara, P | 1 |
| Aoyagi, K | 1 |
| Soori, G | 1 |
| Dillman, RO | 1 |
| Wiemann, MC | 1 |
| Stark, JJ | 1 |
| Tai, F | 1 |
| DePriest, CB | 1 |
| Church, CK | 1 |
| Schulof, R | 1 |
| Yamazaki, S | 1 |
| Endo, H | 1 |
| Hamamoto, T | 1 |
| Baba, M | 1 |
| Joichi, Y | 1 |
| Kaneko, S | 1 |
| Okada, Y | 1 |
| Okuyama, T | 1 |
| Nishino, H | 1 |
| Murphy, BR | 1 |
| Rynard, SM | 1 |
| Einhorn, LH | 1 |
| Loehrer, PJ | 1 |
| Nishimura, N | 1 |
| Kanda, S | 1 |
| Yogi, Y | 1 |
| Kawamura, M | 1 |
| Nakamura, M | 1 |
| Hyakutake, H | 1 |
| Kanetake, H | 1 |
| Saito, Y | 1 |
| Fitz, K | 1 |
| Dexeus, FH | 2 |
| Kilbourn, R | 1 |
| Wallace, S | 1 |
| Sasagawa, T | 1 |
| Munakata, A | 1 |
| Muramatsu, T | 1 |
| Honda, N | 1 |
| Fukatsu, H | 1 |
| Segawa, A | 1 |
| Hirata, N | 1 |
| Senda, H | 1 |
| Hrushesky, WJ | 1 |
| Fujioka, T | 1 |
| Hasegawa, M | 1 |
| Ishikura, K | 1 |
| Nomura, K | 1 |
| Okamoto, T | 1 |
| Tanji, S | 1 |
| Koike, H | 1 |
| Kubo, T | 1 |
| Zaniboni, A | 1 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Montini, E | 1 |
| Ferrari, V | 1 |
| Marini, G | 1 |
| Komeda, H | 1 |
| Horie, M | 1 |
| Takahashi, Y | 1 |
| Kobayashi, S | 1 |
| Yamada, S | 1 |
| Kuriyama, M | 1 |
| Kawada, Y | 1 |
| Asakawa, M | 1 |
| Maekawa, T | 1 |
| Umeda, M | 1 |
| Sakamoto, W | 1 |
| Senju, M | 1 |
| Iseki, T | 1 |
| Tanaka, H | 1 |
| Horii, A | 1 |
| Myoga, H | 1 |
| Tamaki, M | 1 |
| Shinko, Y | 1 |
| Ohta, S | 1 |
| Shigemasa, K | 1 |
| Nogawa, T | 1 |
| Katsube, Y | 1 |
| Fujiwara, A | 1 |
| Masuda, F | 1 |
| Suzuki, M | 1 |
| Ohnishi, T | 1 |
| Nakada, J | 1 |
| Mori, Y | 1 |
| Iizuka, N | 1 |
| Machida, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma[NCT04462445] | Phase 2 | 25 participants (Actual) | Interventional | 2015-06-25 | Completed | ||
| A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer[NCT00058318] | Phase 2 | 43 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma[NCT00053820] | Phase 3 | 670 participants (Anticipated) | Interventional | 2002-07-31 | Completed | ||
| Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)[NCT00496301] | Phase 2 | 40 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients[NCT01182142] | Phase 2 | 51 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma[NCT00042965] | Phase 2 | 60 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma[NCT00003126] | Phase 3 | 69 participants (Actual) | Interventional | 1997-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for fluorouracil and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
TroVax in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines | 2014 |
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.
Topics: Alanine Transaminase; Azetidines; Benzylamines; Carcinoma, Renal Cell; Drug Approval; Europe; Fluoro | 2010 |
Thalidomide therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2003 |
[Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2004 |
Immunotherapy in metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2005 |
Interferon alpha for the treatment of advanced renal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality T | 2005 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as | 1993 |
[Interferon-alpha therapy in hypernephroma].
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alpha; In | 1993 |
European studies of interleukin-2 in metastatic renal cell carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1993 |
[Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Combined Modality | 1999 |
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2000 |
83 trials available for fluorouracil and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De | 2014 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolite | 2015 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal | 2008 |
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2008 |
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dr | 2009 |
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycyt | 2009 |
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Re | 2010 |
Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arcidae; C | 2009 |
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2010 |
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Ca | 2012 |
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Age | 2012 |
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2002 |
Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2002 |
A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 2003 |
[Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug S | 2002 |
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2003 |
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Ther | 2003 |
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progress | 2003 |
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur | 2004 |
Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Interfe | 2004 |
Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyt | 2004 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorourac | 2005 |
Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2005 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ca | 2006 |
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti | 2006 |
Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2007 |
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; De | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2008 |
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Rena | 1995 |
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch | 1995 |
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Blood Cell Count; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Fluorouraci | 1994 |
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.
Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Parent | 1994 |
Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug | 1994 |
Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
Topics: Adult; Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Administration Schedule; Female; | 1993 |
European studies of interleukin-2 in metastatic renal cell carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1993 |
Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Combined | 1996 |
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 1996 |
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac | 1997 |
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; K | 1997 |
[Combination therapy of daily intramuscular injection of interferon-alpha and oral administration of fluorouracil for advanced renal cell carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1998 |
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1998 |
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 1998 |
A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cimetidine; Fema | 1998 |
Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur | 1999 |
Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1999 |
T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 1999 |
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Hu | 2000 |
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2000 |
Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 2000 |
Capecitabine in the treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxy | 2000 |
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Disease- | 2000 |
Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 2000 |
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur | 2000 |
Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2001 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; K | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxy | 2002 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2002 |
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac | 1992 |
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1992 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as | 1989 |
[Comparative clinical study of single and combination therapy of human lymphoblastoid interferon (HLBI) with 5-FU in the treatment of advanced renal cell carcinoma].
Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Fluorouracil; | 1989 |
118 other studies available for fluorouracil and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorouracil; | 2023 |
6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Topics: AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cellular Reprogra | 2020 |
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluo | 2017 |
Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis | 2017 |
Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; Cell | 2017 |
Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.
Topics: Antagomirs; Apoptosis; Benzimidazoles; Carcinoma, Renal Cell; Cation Transport Proteins; Cell Line, | 2017 |
Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance.
Topics: Aldehyde Dehydrogenase; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Lineage; Drug Resista | 2017 |
HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Papil | 2018 |
Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line | 2018 |
Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
Topics: AC133 Antigen; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Fluorouracil; H | 2018 |
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Hel | 2018 |
Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy.
Topics: Antineoplastic Agents; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; | 2014 |
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Hu | 2013 |
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; CDC2 Protein Kinas | 2013 |
HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Fluorouracil; Hepatocyte Nuclear Fac | 2014 |
Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bev | 2015 |
let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; | 2015 |
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2015 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cation | 2008 |
Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transplantat | 2008 |
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2009 |
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; C | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aort | 2010 |
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Ren | 2009 |
Chemo-immunotherapy in RCC: the end of a story.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy, Combination; Fluorouracil; Humans; Immun | 2010 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Ce | 2010 |
Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells.
Topics: Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Adhesion; Cell C | 2010 |
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; | 2011 |
Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Comb | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Com | 2011 |
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumo | 2011 |
Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorodeoxygluc | 2013 |
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin | 2011 |
Investigating cellular responses to novel chemotherapeutics in renal cell carcinoma using SR-FTIR spectroscopy.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Principal Component An | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouracil Dehydrogenase (NADP); Drug Scr | 2003 |
Significance of thymidylate synthase activity in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, T | 2003 |
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouraci | 2003 |
Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; C | 2003 |
Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Drug Screeni | 2004 |
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine | 2004 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials | 2004 |
[Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur | 2004 |
[First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorouracil; Germany | 2004 |
Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dose-Response Relati | 2004 |
Long-term treatment of metastatic renal-cell carcinoma with fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorou | 2004 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2004 |
Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Topics: Administration, Cutaneous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Immunochemotherapy of metastatic renal cell carcinoma: report of 28 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 2005 |
Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 2; | 2005 |
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; C | 2005 |
Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Disease-Free Survival; Female; | 2005 |
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea | 2005 |
Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluoro | 2006 |
Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carc | 2006 |
Gene therapy with TRAIL against renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality | 2006 |
Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 2007 |
Renal cell carcinoma in children: experience of a single center.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Car | 2007 |
Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Fluorouraci | 2007 |
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Caspases; Deoxycytidine; Drug Synergism; Flow C | 2007 |
Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma.
Topics: Aminoquinolines; Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Enzyme Activation; F | 2007 |
[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, R | 2007 |
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Comb | 2007 |
Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival.
Topics: Adult; Aged; Carcinoma, Renal Cell; Eosinophils; Female; Fluorouracil; Humans; Immunotherapy; Interf | 2007 |
Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; CD4-Positive T-Lympho | 2008 |
[Chemotherapy of renal cell carcinoma. 3. Single-agent therapy with FT-207 or vinblastine].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Huma | 1984 |
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Case-Control Studies; Combined Modality Therapy; Drug | 1996 |
Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Interleukin-2; Kidney Neoplasms; Mal | 1995 |
Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Fl | 1995 |
Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Ambulatory Care; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil | 1995 |
5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle.
Topics: Antigens, Differentiation, T-Lymphocyte; Carcinoma, Renal Cell; CD2 Antigens; Cell Adhesion; Cell Ad | 1993 |
Renal cell cancer: is there long-term survival advantage from cytokine treatment?
Topics: Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neop | 1994 |
[Current status of chemotherapy for renal cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney | 1994 |
[Immunotherapy of renal cell carcinoma from an urological viewpoint].
Topics: Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Immunotherapy, Active; Interferon-alpha; Interl | 1993 |
[Immunotherapy in metastatic cancer of the kidney].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Synergism; Drug | 1995 |
Carpal tunnel syndrome associated with interleukin-2 therapy.
Topics: Adult; Carcinoma, Renal Cell; Carpal Tunnel Syndrome; Drug Therapy, Combination; Female; Fluorouraci | 1996 |
[Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; I | 1996 |
Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality Therapy; Drug | 1996 |
[Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Chemothe | 1997 |
Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1997 |
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1997 |
IL-6 is a survival prognostic factor in renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Biopterins; C-Reactive Protein; Carcinoma, | 1997 |
Hyperplasia of axillary nodes in patients undergoing immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Renal Cell; Fluorouracil; Humans; | 1997 |
Enhancement of 5-fluorouracil cytotoxicity by folinic acid in different cell-lines of human renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cell Division; Cell Survival; Drug Synergism; Fluorouracil; Humans; Kidney Ne | 1996 |
[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1997 |
[Immunotherapeutic treatment for metastatic renal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour | 1998 |
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Screening Assays | 1998 |
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1999 |
Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil; Follo | 1999 |
Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arachnoid; Carcinom | 1999 |
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon-alpha; Kidn | 1999 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; C | 1999 |
Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Topics: Acridine Orange; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents | 2000 |
Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil.
Topics: Animals; Carcinoma, Renal Cell; Combined Modality Therapy; DNA, Complementary; Female; Fluorouracil; | 2000 |
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com | 2000 |
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxyc | 2001 |
Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil.
Topics: Amino Acid Chloromethyl Ketones; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Renal Cell; Casp | 2001 |
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosi | 2002 |
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Renal C | 2001 |
Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Division; DNA, Neoplasm; D | 2001 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh | 2002 |
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Floxuridine; Fluorouracil; Humans; Kidney; K | 2002 |
Secretion of autocrine growth-promoting activity by renal-carcinoma cells treated with 5-fluorouracil.
Topics: 3T3 Cells; Animals; Carcinoma, Renal Cell; DNA, Neoplasm; Fluorouracil; Growth Substances; Humans; K | 1992 |
[Combined effects of alpha-interferon and anticancer drugs against renal cell carcinoma].
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Renal Cell; Combined Modality Therapy; Doxorub | 1990 |
Concentration of 5-fluorouracil in renal cells from cancer patients administered a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney; | 1991 |
[Combination chemotherapy of human renal cell carcinoma in athymic nude mice with human lymphoblastoid interferon (HLBI) and UFT, 5-Fu].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Th | 1990 |
[Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Screening Assay | 1990 |
Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Evaluation; | 1989 |
[A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Kidney Neopla | 1989 |
[Synchronous double cancers in the ovary and kidney--a case report].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Com | 1988 |
[5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney | 1985 |